TY - JOUR
T1 - Clinical outcomes with paliperidone palmitate 3-monthly injection as monotherapy
T2 - observational 3-year follow-up of patients with schizophrenia
AU - Clark, Ivana
AU - Wallman, Phoebe
AU - Gee, Siobhan
AU - Taylor, David
N1 - Funding Information:
This work was supported by Janssen UK (grant number 1126389).
Funding Information:
D.T. reports research funding from Janssen and speaker’s honoraria from Janssen, Otsuka, Viatris, and Recordati. I.C., P.W., and S.G. declare none.
Publisher Copyright:
© 2024 Cambridge University Press. All rights reserved.
PY - 2024/3/7
Y1 - 2024/3/7
N2 - BACKGROUND: Paliperidone palmitate 3-monthly (PP3M) has been tested in 1-year controlled studies. The aim of this study was to examine the relapse outcomes with PP3M monotherapy at 3 years in patients with schizophrenia.METHODS: This was an observational, non-interventional study of patients started on PP3M according to their clinical need. All patients had a diagnosis of schizophrenia (ICD-10 F20) and were between 18 and 65 years of age. The study took place in a mental health facility in South East London, UK.RESULTS: Among the 166 patients who started PP3M, 97 (58%) met inclusion criteria and were observed for 36 months. In total, five patients (5%) experienced a relapse (defined as step-up in clinical care) while on PP3M. There were no relapses between months 18 and 36. Of the original 97 patients, 56 (58%) remained on PP3M monotherapy at 3 years, and 71 (73%) remained on either PP3M or paliperidone palmitate one-monthly. Reasons for discontinuation of PP3M included patient refusal (n = 11, 33% of discontinuations) and adverse effects in (n = 8, 24%).CONCLUSION: PP3M is a highly effective monotherapy treatment for reducing relapse in people with schizophrenia.
AB - BACKGROUND: Paliperidone palmitate 3-monthly (PP3M) has been tested in 1-year controlled studies. The aim of this study was to examine the relapse outcomes with PP3M monotherapy at 3 years in patients with schizophrenia.METHODS: This was an observational, non-interventional study of patients started on PP3M according to their clinical need. All patients had a diagnosis of schizophrenia (ICD-10 F20) and were between 18 and 65 years of age. The study took place in a mental health facility in South East London, UK.RESULTS: Among the 166 patients who started PP3M, 97 (58%) met inclusion criteria and were observed for 36 months. In total, five patients (5%) experienced a relapse (defined as step-up in clinical care) while on PP3M. There were no relapses between months 18 and 36. Of the original 97 patients, 56 (58%) remained on PP3M monotherapy at 3 years, and 71 (73%) remained on either PP3M or paliperidone palmitate one-monthly. Reasons for discontinuation of PP3M included patient refusal (n = 11, 33% of discontinuations) and adverse effects in (n = 8, 24%).CONCLUSION: PP3M is a highly effective monotherapy treatment for reducing relapse in people with schizophrenia.
KW - Humans
KW - Paliperidone Palmitate/adverse effects
KW - Schizophrenia/drug therapy
KW - Follow-Up Studies
KW - Hospitals, Psychiatric
KW - Recurrence
UR - http://www.scopus.com/inward/record.url?scp=85187197853&partnerID=8YFLogxK
U2 - 10.1192/j.eurpsy.2024.13
DO - 10.1192/j.eurpsy.2024.13
M3 - Article
C2 - 38450540
SN - 0924-9338
VL - 67
SP - e15
JO - European psychiatry : the journal of the Association of European Psychiatrists
JF - European psychiatry : the journal of the Association of European Psychiatrists
IS - 1
M1 - e15
ER -
